TScan Therapeutics Statistics
Total Valuation
TCRX has a market cap or net worth of $101.30 million. The enterprise value is -$67.53 million.
Important Dates
The last earnings date was Tuesday, August 12, 2025, before market open.
Earnings Date | Aug 12, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
TCRX has 56.75 million shares outstanding. The number of shares has increased by 7.21% in one year.
Current Share Class | 52.47M |
Shares Outstanding | 56.75M |
Shares Change (YoY) | +7.21% |
Shares Change (QoQ) | +129.24% |
Owned by Insiders (%) | 0.76% |
Owned by Institutions (%) | 54.15% |
Float | 44.21M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 14.43 |
Forward PS | 17.48 |
PB Ratio | 0.57 |
P/TBV Ratio | 0.58 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
Current Ratio | n/a |
Quick Ratio | n/a |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -46.38 |
Financial Efficiency
Return on equity (ROE) is -63.33% and return on invested capital (ROIC) is -34.47%.
Return on Equity (ROE) | -63.33% |
Return on Assets (ROA) | -26.77% |
Return on Invested Capital (ROIC) | -34.47% |
Return on Capital Employed (ROCE) | n/a |
Revenue Per Employee | $35,697 |
Profits Per Employee | -$701,410 |
Employee Count | 195 |
Asset Turnover | 0.02 |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -70.50% in the last 52 weeks. The beta is 0.99, so TCRX's price volatility has been similar to the market average.
Beta (5Y) | 0.99 |
52-Week Price Change | -70.50% |
50-Day Moving Average | 1.68 |
200-Day Moving Average | 2.36 |
Relative Strength Index (RSI) | 53.55 |
Average Volume (20 Days) | 265,424 |
Short Selling Information
The latest short interest is 1.72 million, so 3.03% of the outstanding shares have been sold short.
Short Interest | 1.72M |
Short Previous Month | 1.83M |
Short % of Shares Out | 3.03% |
Short % of Float | 3.89% |
Short Ratio (days to cover) | 5.32 |
Income Statement
In the last 12 months, TCRX had revenue of $6.96 million and -$136.78 million in losses. Loss per share was -$2.41.
Revenue | 6.96M |
Gross Profit | -8.57M |
Operating Income | -144.24M |
Pretax Income | -96.80M |
Net Income | -136.78M |
EBITDA | -141.14M |
EBIT | -144.24M |
Loss Per Share | -$2.41 |
Full Income Statement Balance Sheet
The company has $169.39 million in cash and n/a in debt, giving a net cash position of $169.39 million or $2.99 per share.
Cash & Cash Equivalents | 169.39M |
Total Debt | n/a |
Net Cash | 169.39M |
Net Cash Per Share | $2.99 |
Equity (Book Value) | 176.71M |
Book Value Per Share | 3.11 |
Working Capital | 169.39M |
Full Balance Sheet Margins
Gross Margin | -123.16% |
Operating Margin | -2,072.07% |
Pretax Margin | -1,964.88% |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
TCRX does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -7.21% |
Shareholder Yield | -7.21% |
Earnings Yield | -134.27% |
FCF Yield | n/a |
Analyst Forecast
The average price target for TCRX is $9.50, which is 432.21% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $9.50 |
Price Target Difference | 432.21% |
Analyst Consensus | Strong Buy |
Analyst Count | 6 |
Revenue Growth Forecast (5Y) | 114.25% |
EPS Growth Forecast (5Y) | -24.27% |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 1 |